Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00418951 · ClinicalTrials.gov registry record · Phase 2
Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00418951: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00418951 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00418951, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to compare the effectiveness of liposomal amphotericin B given three times per week , versus liposomal amphotericin B given once per week, versus oral voriconazole in the prevention of fungal infections in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes MDS who are receiving chemotherapy. The safety of these treatments will also be studied and compared.
Interventions
- DRUG Voriconazole
- DRUG Liposomal amphotericin B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00418951
The ClinicalTrials.gov registry entry for NCT00418951 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Voriconazole is the first listed.
NCT00418951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00418951 about?
NCT00418951 is a clinical study titled "Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections". The goal of this clinical research study is to compare the effectiveness of liposomal amphotericin B given three times per week , versus liposomal amphotericin B given once per week, versus oral voriconazole in the prevention of fungal infections in patients with acute myeloid leukemia (AML) or myel...
What is the current status of trial NCT00418951?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2006-11. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00418951?
The interventions under investigation include: Voriconazole (DRUG), Liposomal amphotericin B (DRUG).
Who is sponsoring clinical trial NCT00418951?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.